文献速递甲状腺与颈部外科

低中复发风险分化型甲状腺癌全甲状腺切除或甲状腺叶切除与生活质量的相关性

Association of Total Thyroidectomy or Thyroid Lobectomy With the Quality of Life in Patients With Differentiated Thyroid Cancer With Low to Intermediate Risk of Recurrence.
PubMed 文献 · JAMA Surg · 2022-01-01

这项前瞻性观察性纵向队列研究纳入2018年10月1日至2019年9月31日就诊的1060例低中复发风险分化型甲状腺癌患者,其中563例行甲状腺叶切除、497例行全甲状腺切除,术前及术后1、3、6、12个月用3份生活质量问卷评估。全甲状腺切除组在术后1和3个月的生活质量问题多于甲状腺叶切除组(含1至4厘米肿瘤亚组),但术后6和12个月几乎所有差异消失。作者认为生活质量与手术范围无关,若短期追求更好生活质量可优先选择甲状腺叶切除。

要点

  • 全甲状腺切除组术后1和3个月的生活质量问题多于甲状腺叶切除组,含1至4厘米肿瘤亚组。
  • 术后6和12个月时,两组几乎所有生活质量差异消失。
  • 作者认为低中复发风险分化型甲状腺癌患者的生活质量与手术范围无关。

核心结论

  • 作者认为低中复发风险分化型甲状腺癌患者的生活质量与手术范围无关,生活质量可能不是手术决策的重要考虑因素。
  • 作者指出若短期追求更好的生活质量,可优先选择甲状腺叶切除。

研究设计与样本

  • 前瞻性观察性纵向队列研究,纳入2018年10月1日至2019年9月31日于中国中山大学附属第一医院诊断的低中复发风险分化型甲状腺癌患者。
  • 共1060例 eligible 患者,其中563例行甲状腺叶切除(438名女性[77.8%],中位[IQR]年龄38[31-45]岁),497例行全甲状腺切除(390名女性[78.5%],中位[IQR]年龄38[32-48]岁)。
  • 术前评估并于术后1、3、6、12个月随访,使用3份生活质量相关问卷(欧洲癌症研究与治疗组织生活质量问卷第3.0版、医院焦虑抑郁量表、甲状腺癌特异性生活质量问卷),并监测血清促甲状腺激素水平、并发症和患者满意度。

主要发现

  • 与甲状腺叶切除组(包括1至4厘米肿瘤亚组)相比,全甲状腺切除组在术后1和3个月经历更多术后生活质量问题。
  • 术后6和12个月时,几乎所有差异消失。

临床怎么用

  • 作者认为生活质量可能不是低中复发风险分化型甲状腺癌手术决策的重要考虑因素。
  • 作者指出若短期追求更好的生活质量,可优先选择甲状腺叶切除。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Owing to the good prognosis of differentiated thyroid cancer (DTC), guidelines recommend total thyroidectomy (TT) or thyroid lobectomy (TL) as surgical treatment for DTC with low to intermediate risk of recurrence. However, the association of these surgeries with the health-related quality of life (HRQOL) of patients with DTC with low to intermediate risk of recurrence is unclear. OBJECTIVE: To longitudinally compare the HRQOL of patients with DTC undergoing different surgeries. DESIGN, SETTING, AND PARTICIPANTS: This prospective observational longitudinal cohort study enrolled patients diagnosed with DTC with low to intermediate risk of recurrence at the First Affiliated Hospital, Sun Yat-sen University, China, from October 1, 2018, to September 31, 2019. Eligible patients were categorized into TL and TT groups according to the surgery they underwent. They were evaluated preoperatively and followed up at 1, 3, 6, and 12 months postoperatively using 3 HRQOL-related questionnaires (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, version 3.0; Hospital Anxiety and Depression Scale; and Thyroid Cancer-Specific Quality of Life Questionnaire); serum thyrotropin levels, complications, and patient satisfaction were also monitored. Data were analyzed to compare the HRQOL of patients undergoing different surgeries at different time points. EXPOSURES: Total thyroidectomy or TL. MAIN OUTCOMES AND MEASURES: The primary end point was HRQOL (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, version 3.0; Hospital Anxiety and Depression Scale; and Thyroid Cancer-Specific Quality of Life Questionnaire) at different time points, and the secondary end points were postoperative complications, thyrotropin level, and patient satisfaction. RESULTS: Of the 1060 eligible patients, 563 underwent TL (438 women [77.8%]; median [IQR] age, 38 [31-45] years), and 497 underwent TT (390 women [78.5%]; median [IQR] age, 38 [32-48] years). Compared with the TL group, including the 1- to 4-cm tumor subgroup, the TT group experienced more postoperative HRQOL problems at 1 and 3 months postoperatively. However, nearly all the differences disappeared at 6 and 12 months postoperatively. CONCLUSIONS AND RELEVANCE: Results of this study suggest that HRQOL of patients with DTC with low to intermediate risk of recurrence is not associated with the extent of surgery, and HRQOL may not be an important consideration when making surgical decisions. If better HRQOL is requested in the short term, TL may be preferred.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. Chen W, Li J, Peng S, et al. Association of Total Thyroidectomy or Thyroid Lobectomy With the Quality of Life in Patients With Differentiated Thyroid Cancer With Low to Intermediate Risk of Recurrence. JAMA Surg. 2022. PMID: 34935859. doi:10.1001/jamasurg.2021.6442

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。